Mussen 1997 On Drug Abuse

MDMA, ketamine, and GHB are by no means the only drugs found at clubs, raves, or circuit parties. They are, however, the most emblematic. Attendees also use more traditional drugs, such as LSD and other hallucinogens. Marijuana is perennially popular, and alcohol use is also common. Furthermore, each week seems to bring a report of some "new" drug of abuse. Often this is just an older, well-known drug, packaged differently or with a new name, but the effect on a new generation of users will be just as devastating.

Drugs such as these are being increasingly used at clubs, often in combination, and often by very young people. This is cause for concern for several reasons. The younger a person is when he or she begins to use drugs, and the more often he or she uses them, the more likely he or she is to develop serious problems with these or other substances. In the future, we are likely to see more and more use of such drugs and the problems that come with their use.

When the evidence of MDMA's neurotoxicity was lacking, and what research existed on GHB and marijuana was not as compelling, individuals concerned with the public's safety could afford to be less alarmed. The mount-

ing bodies of evidence, however, and the possible public health implications, are a call for effective prevention and education interventions.


Abel, E. L. (1980). Marijuana: The first twelve thousand years. New York: Plenum Press.

Ajaelo, I., Koenig, K., & Snoey, E. (1998). Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med, 5, 939840.

American Academy of Ophthalmology. (1992, June). The use of marijuana in the treatment of glaucoma. Statement by the Board of Directors of the American Academy of Ophthalmology, San Francisco.

Ames, D., & Wirshing, W. (1993). Ecstasy, the serotonin syndrome, and neuroleptic malignant syndrome—a possible link? JAMA, 269, 869-870.

Arseneault, L. Cannon, M., Witton, J., & Murray, R. M. (2004). Causal association between cannabis and psychosis: Examination of the evidence. Br J Psychiatry, 194, 110-117.

Beck, J. (1990). The public health implications of MDMA use. In S. J. Peroutka (Ed.), Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA (pp. 77-103). Boston: Kluwer Academic.

Beck, J., & Rosenbaum, M. (1994). Pursuit of Ecstasy: The MDMA experience. Albany: State University of New York Press.

Bellis, M. A., Hale, G., Bennett, A., Chaudry, M., & Kilfoyle, M. (2000). Ibiza uncovered: Changes in substance use and sexual behavior amongst young people visiting an international nightlife resort. Int J Drug Policy, 11 , 235-244.

Block, R. I. (1996). Does heavy marijuana use impair human cognition and brain function? JAMA, 275, 560-561.

Bonnie, R. J., & Whitebread, C. H. (1974). The marijuana conviction: A history of marijuana prohibition in the United States. Charlottesville: University of Virginia Press.

Boys, A., Lenton, S., & Norcross, K. (1997). Polydrug use at raves by a Western Australian sample. Drug Alcohol Rev, 16, 227-234.

Bubser, M., Keseberg, U., Notz, P. K., & Griffiths, P. (1992). Differential behavioral and neurochemical effects of competitive and noncompetitive NMDA receptor antagonists in rats. Eur J Pharmacol, 229, 75-82.

Budney, A. J., Moore, B. A., Vandrey, R. G., & Hughes, J. R. (2003). The time course and significance of cannabis withdrawal. J Abnorm Psychol, 112, 393-402.

Buffum, J., & Moser, C. (1986). MDMA and human sexual function. J Psychoactive Drugs, 18, 355-359.

Burgess, C., O'Donoghoe, A., & Gill, M. (2000). Agony and ecstasy: A review of MDMA effects and toxicity. Eur Psychiatry, 15, 287-294.

CESAR, the Center for Substance Abuse Research. (2004). Inhalant abuse: Nothing to sniff at. CESAR Fax, 13(12).

Chin, M. Y., Kreutzer, R. A., & Dyer, J. E. (1992). Acute poisoning from gamma-hydroxybutyrate in California. West J Med, 156, 380-384.

Chopra, G. S., & Smith, J. W. (1974). Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry, 30, 24-27.

Cohen, R. (1998). The love drug: Marching to the beat of Ecstasy. Binghamton, NY: Hayworth Press.

Cooper, M. (1996, January 28). "Special K": Rough catnip for clubgoers. New York Times, p. A-6.

Cotman, C. W., & Monaghan, D. T. (1987). Chemistry and anatomy of excitatory amino acid systems. In H. Y. Meltzer (Ed.), Psychopharmacology: The third generation of progress (pp. 194-210). New York: Raven Press.

Creighton, F., Black, D., & Hyde, C. (1991). Ecstasy psychosis and flashbacks. Br J Psychiatry, 159, 713-715.

Crider, R. A. (1986). Phencyclidine: Changing abuse patterns. In D. H. Clouet (Ed.), Phencyclidine: An update (pp. 163-173). Rockville, MD: U.S. Department of Health and Human Services.

Curran, H. V., & Monaghan, L. (2001). In and out of the K-hole: A comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction, 96, 749-760.

Deas, D., Gerding, L., & Hazy, J. (2000). Marijuana and panic disorder. J Am Acad Child Adolesc Psychiatry, 39, 1467.

Delgarno, P. J., & Shewan, D. (1996). Illicit use of ketamine in Scotland. J Psychoactive Drugs, 28, 191-199.

Demirkiran, M., Jankovic, J., & Dean, J. (1996). Ecstasy intoxication: An overlap between serotonin syndrome and neuroleptic malignant syndrome. Clin Neuro-

pharmacol, 19, 157-164.

Dotson, J., Ackerman, D., &West, L. (1995). Ketamine abuse. J Druglssues, 25, 751-757.

Eisner, B. (1986). Ecstasy: The MDMA story. Boston: Little, Brown.

Eisner, B. (1993). Ecstasy: The MDMA story (2nd ed.). Berkeley, CA: Ronin.

Feeney D. (1976). Marijuana use among epileptics. JAMA, 235, 1105.

Fox, H. C., Parrott, A. C., & Turner, J. J. (2001). Ecstasy use: Cognitive deficits related to dosage rather than self reported problematic use of the drug. J Psychopharmacol, 15, 273-281.

Fort Dodge Laboratories. (1997). Ketaset [Package insert]. Fort Dodge, IA: Author.

Gallimberti, L., Canton, G., Gentile, N., Ferri, M., Cibin, M., Ferrara, S. D., et al. (1989). Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. Lancet, 30, 787-789.

Galloway, G. P., Frederick, S. L., Staggers, F. E., Jr., Gonzales, M., Stalcup, S. A., & Smith, D. E. (1997). Gamma-hydroxybutyrate: An emerging drug of abuse that causes physical dependence. Addiction, 92, 89-96.

Garfield, J. M., Garfield, F. B., Stone, J. G., Hopkins, D., & Johns, L. A. (1994). A comparison of psychologic responses to ketamine and thiopental-nitrous oxide-halo-thane anesthesia. Anesthesiology, 36, 329-338.

Gay Men's Health Crisis (McDowell, D., Consultant). (1997). Drugs in partyland [Brochure]. New York: GMHC Press.

Graeme, K. A. (2000). New drugs of abuse. EmergMed Clin North Am, 18(4), 625-636.

Green, A., Cross, A., & Goodwin, G. (1995). Review of pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology, 119, 247-260.

Grinspoon L., & Bakalar, J. B. (1995). Marijuana as medicine: A plea for reconsideration. JAMA, 273, 1875-1876.

Hampton, R. Y., Medzihradsky, F., Woods, J. H., & Dahlstrom, P. J. (1982). Stereo-specific binding of 3H phencyclidine in brain membranes. Life Sci, 30, 2147-2154.

Hechler, V., Goebaille, S., & Maitre, M. (1992). Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and mid-brain as revealed by quantitative autoradiograph. Brain Res, 572, 345-348.

Hepler, R. S., & Petrus, R. J. (1976). Experiences with administration of marijuana to glaucoma patients. In S. Cohen & R. C. Stillman (Eds.), The therapeutic potential of marijuana (pp. 63-75). New York: Plenum Medical Books.

Hermle, L., Spitzer, M., Borchardt, D., Kovar, K. A., & Gouzoulis, E. (1993). Psychological effects of MDE in normal subjects. Neuropsychopharmacology, 8, 171—176.

Holland, J. (2001). Ecstasy: The complete guide. Rochester, VT: Panic Street Press.

Holmes, S. B., Banerjee, A. K., & Alexander, W. D. (1999). Hyponatremia and seizures after ecstasy use. Postgrad Med J, 75, 32-43.

Iversen, L. L., & Snyder, S. H. (1999). The science of marijuana. New York: Oxford University Press.

Jansen, K. (1990). A review of the non-medical uses of ketamine: Use, uses, and consequences. J Psychoactive Drugs, 32, 419-433.

Johnson, L. D., O'Malley, P. M., & Bachman, J. G. (2002). Monitoring the future national results on adolescent drug use: Overview of key findings, 2001 (NIH Publication No. 02-5105). Bethesda, MD: National Institute on Drug Abuse.

Kassirer, J. P. (1999). Should medical journals try to influence political debates? N Engl J Med, 340, 466-467.

Khalant, H. (2001). The pharmacology and toxicology of "Ecstasy" (MDMA) and related drugs. Can Med Assoc J, 165, 917-928.

Koesters, S. C., Rogers, P. D., & Rajasingham, C. R. (2002). MDMA ("Ecstasy") and other "club drugs": The new epidemic. Pediatr Clin North Am, 49, 415-433.

Kris, M. G., Cubeddu, L. X., Gralla, R. J., Cupissol, D., Tyson, L. B., Venkatraman, E., & Homesley, H. D. (1996). Are more antiemetic trials with a placebo necessary?: Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer, 78, 2193-2198.

Krystal, J. H., Karper, L. P., Seibyl, J. P., Freeman, G. K., Delaney, R., Bremner, J. D., et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist ketamine in humans. Arch Gen Psychiatry, 51, 199-214.

Lammers, G. J., Arends, J., Declerck, A. C., Ferrari, M. D., Schouwink, G., & Troost, J. (1993). Gammahydroxybutyrate and narcolepsy: A double blind placebo controlled study. Sleep, 16, 216-220.

Lee, S., & McDowell, D. M. (2003). Polysubstance use (GHB, MDMA, and other club drugs) by circuit party attendees. Am J Addictions, 181-186.

Leister, M. P., Grob, C. S., Bravo, G. L., & Walsh, R. N. (1992). Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis, 180, 345354.

Li, J., Stokes, S., & Woeckener, A. (1998). A tale of novel intoxication: A review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann EmergMed, 31, 729-736.

Lilly, J. C. (1978). The scientist: A novel autobiography. New York: Lippincott.

Ling, L. H., Marchant, C., Buckley, N. A., Prior, M., & Irvine, R. J. (2001). Poisoning with the recreational drug paramethoxyamphetamine ("death"). Med J Aust, 174, 453-455.

Lynskey, M., & Hall, W. (2000). The effects of adolescent cannabis use on educational attainment: A review. Addiction, 95, 1621-1630.

Malhotra, A. K., Pinals, D. A., Weingartner, H., Sirocco, K., Missar, C. D., Pickar, D., & Breier, A. (1996). NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology, 14, 301-307.

Mamelak, M., Scharf, M. B., & Woods, M. (1986). Treatment of narcolepsy with gamma-hydroxybutyrate: A review of clinical and sleep laboratory findings. Sleep, 9, 285-259.

Marmor, J. B. (1998). Medical marijuana. West J Med, 168, 540-543.

Maurer, M., Henn, V., Dittrich, A., & Hofmann, A. (1990). Delta-9-tetrahydro-cannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci, 240, 1-4.

McCabe, E. R., Layne, E. C., Sayler, D. F., Slusher, N., & Bessman, S. P. (1971). Synergy of ethanol and a natural soporific: Gamma hydroxybutyrate. Science, 171, 404-406.

McCann, U. D., Eligulashvili, W., & Ricaurte, G. A. (2000). (+/-) 3,4-Methyl-entdioxymethamphetamine ("Ecstasy")-induced serotonin neurotoxicity: Clinical studies. Neuropsychobiology, 42, 11-16.

McCann, U. D., & Ricaurte, G. (1991). Lasting neuropsychiatric sequelae of methyl-enedioxymethamphetamine ("Ecstasy") in recreational users. J Clin Psychopharma-col, 11, 302-305.

McCann, U. D., & Ricaurte, G. (1993). Reinforcing subjective effects of 3,4-methyl-enedioxymethamphetamine ("Ecstasy") may be separable from its neurotoxic actions: Clinical evidence. J Clin Psychopharmacol, 13, 214-217.

McCann, U. D., Ridenour, A., Shaham, Y., & Ricaurte, G. A. (1994). Serotonin neurotoxicity after (±)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): A controlled study in humans. Neuropsychopharmacology, 10, 129-138.

McCann, U. D., Slate, S., & Ricaurte, G. (1996). Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA: "Ecstasy"). Drug Safety, 15, 107115.

McDowell, D., & Kleber, H. (1994). MDMA, its history and pharmacology. Psychiatr Ann, 24, 127-130.

McDowell, D., & Spitz, H. (1999). Substance abuse: From principles to practice. New York: Brunner/Mazel.

McDowell, D. M. (1998). Testimony to House Judiciary Committee. Available at

McKenna, D., & Peroutka, S. (1990). The neurochemistry and neurotoxicity of 3,4-methylenedioxymethamphetamine, "Ecstasy." J Neurochem, 54, 14-22.

Meyer, J. S., Greifenstein, F., & DeVault, M. (1959). A new drug causing symptoms of sensory depravation. J Nerv Ment Dis, 129, 54-61.

Moretti, R. J., Hassan, S. Z., Goodman, L. I., & Meltzer, H. Y. (1984). Comparison of ketamine and thiopental in healthy volunteers: Effects on mental status, mood, and personality. Anesth Analg, 63, 1087-1096.

Montoya, A., Sorrentino, R., Lucas, S., & Price, B. (2002). Long-term neuropsychiatry consequences of "Ecstasy" (MDMA): A review. Harv Rev Psychiatry, 10(4), 212220.

Morgan, M. J. (2000). Ecstasy (MDMA): A review of its possible persistent psychological effects. Psychopharmacology, 152, 230-248.

National Eye Institute. (1997, February 18). The use of marijuana for glaucoma. Retrieved February 1, 2004, from

National Institute on Drug Abuse. (1979). Diagnosis and treatment of phencyclidine (PCP) toxicity [Brochure]. Rockville, MD: Author.

National Institutes of Health. (1997, February 19-20). Workshop on the medical utility of marijuana. Retrieved February 1, 2004, from medicalmarijuana.htm

Nelson, K., Walsh, D., Deeter, P., & Sheehan, F. (1994). A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care, 10, 14-18.

Oye, N., Paulsen, O., & Maurset, A. (1992). Effects of ketamine on sensory perception: Evidence for a role of N-methyl D-aspartate receptors. J Pharmacol Exp Ther, 260, 1209-1213.

Pandit, S. K., Kothary, S. P., & Kumar, S. M. (1980). Low dose intravenous infusion technique with ketamine. Anesthesia, 35, 669-675.

Peroutka, S. (1990). Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA. Boston: Kluwer Academic.

Peroutka, S., Newman, H., & Harris, H. (1998). Subjective effects of 3,4-MDMA in recreational abusers. Neuropsychopharmacology, 11, 273-277.

Pope, H. G., & Yurgelun-Todd, D. (1996). The residual cognitive effects of heavy marijuana use in college students. JAMA, 275, 521-527.

Rattray, M. (1991). Ecstasy: Towards an understanding of the biochemical basis of the actions of MDMA. Essays Biochem, 26, 77-87.

Ricaurte, G. A., & McCann, U. D. (2001). Assessing long-term effects of MDMA (Ecstasy). Lancet, 358, 1831-1832.

Ricaurte, G. A., McCann, U. D., Szabo, Z., & Scheffel, U. (2000). Toxicodynamics and long-term toxicity of the recreational drug 3,4-methylenedicoxymethampheta-mine (MDMA, "Ecstasy"). Toxicol Lett, 112-113, 143-146.

Ricaurte, G. A., Yuan, J., Hatzidiitrious, G., Cord, B. J., & McCann, U. D. (2002). Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA ("Ecstasy"). Science, 297, 2260-2263.

Rodgers, J. (2000). Cognitive performance amongst recreational users of "Ecstasy." Psychopharmacology, 151, 19-24.

Sallan, S. E., Zinberg, N. E., & Frei, E. (1975). Antiemetic effect of delta-9-tetra-hydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med, 293, 795-797.

Schifano, F. (1991). Chronic atypical psychosis associated with MDMA ("Ecstasy") abuse. Lancet, 338, 1335.

Schwartz, R. (1991). Heavy marijuana use and recent memory impairment. Psychiatr Ann, 21 , 80-83.

Schwartz, R. H. (2002). Marijuana: A decade and a half later, still a crude drug with underappreciated toxicity. Pediatrics, 109, 284-289.

Schwartz, R. H., & Miller, N. S. (1997). MDMA (Ecstasy) and the rave: A review. Pediatrics, 100, 705-708.

Scrima, L., Hartman, P. G., Johnson, F. H., Jr., Thomas, E. E., & Hiller, F. C. (1990). The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: A double-blind study. Sleep, 13, 479-490.

Shannon, M. (2000). Methylenediocyamphetimine (MDMA, Ecstasy). Ped Emer Care, 16, 377-380.

Shulgin, A. (1986). The background and chemistry of MDMA. J Psychoactive Drugs, 18, 291-304.

Shulgin, A. (1990). History of MDMA. In S. J. Peroutka (Ed.), Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA (pp. 1-20). Boston: Kluwer Academic.

Siegel, R. K. (1984). The natural history of hallucinogens. In B. L. Jacobs (Ed.), Hallucinogens: Neurochemistry, behavioral, and clinical perspectives (pp. 1-17). New York: Raven Press.

Solowij, N. (1998). Cannabis and cognitive functioning. Cambridge, UK: Cambridge University Press.

Solowij, N., Michie, P. T., & Fox, A. M. (1995). Differential impairments of selective attention due to frequency and duration of cannabis use. Biol Psychiatry, 37, 731739.

Sprague, J. E., Everman, S. L., & Nichols, D. E. (1998). An integrated hypothesis for the serotonergic axonal loss induced by 3,4- methylenedioxymethamphetamine. Neurotoxicology, 19, 427-441.

Sugiura, T., & Waku, K. (2002). Cannabinoid receptors and their endogenous ligands. J Biochem, 132, 7-12.

Takahara, J., Yunoki, S., Yakushiji, W., Yamauchi, J., Yamane, Y., & Ofuji, T. (1977). Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and pro-lactin release in humans. J Clin Endocrinol Metab, 44, 1014-1018.

Tramer, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001). Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. Br Med J, 323, 16-32.

Tunnicliff, G., & Raess, B. U. (2002). Gamma-hydroxybutyrate (orphan medical). Curr Opin Investig Drugs, 3, 278-283.

Turner, J. J., & Parrott, A. C. (2000). "Is MDMA a human neurotoxin?": Diverse views from the discussants. Neuropsychobiology, 42(1), 42-48.

United Nations. (1997). World drug report. Retrieved February 2, 2004, from

Verkes, R. J., Gijsman, H. J., Pieters, M. S., Schoemaker, R. C., de Visser, S., Kuijpers, M., et al. (2001). Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology, 153, 196-202.

Vickers, M. D. (1969). Gamma-hydroxybutyric acid. Int Anesth Clin, 71, 75-89.

Vinciguerra, V., Moore, T., & Brennan, E. (1988). Inhalation marijuana as an antiemetic for cancer chemotherapy. NY State Med J, 88, 525-527.

Walgate, R. (2003, September 16). Retracted Ecstasy paper "An outrageous scandal." The Scientist. Retrieved February 2, 2004, from


Walton, R. (1938). America's new drug problem. Philadelphia: Lippincott.

Watson, L., & Beck, J. (1986). New Age seekers: MDMA use as an adjunct to spiritual pursuit. J Psychoactive Drugs, 23, 261- 270.

Weir, E. (2000). Raves: A review of the culture, the drugs and the prevention of harm. Can Med Assoc J, 162, 1843-1848.

Winstock, A. R., Griffiths, P., & Stewart, D. (2001). Drugs and the dance music scene: A survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend, 64, 9-17.

Zagnoni, P. G., & Albano, C. (2002). Psychostimulants and epilepsy. Epilepsia, 43, 2831.

Defeat Drugs Death

Defeat Drugs Death

This Book Is One Of The Most Valuable Resources In The World When It Comes To Helpful Info On Avoiding And Beating A Fatal Drug Addiction!

Get My Free Ebook

Post a comment